BioNTech SE was granted Fast Track Designation from the FDA for BNT111, an investigational cancer immunotherapy for the potential treatment of advanced melanoma. BNT111 is the lead product candidate from BioNTech’s FixVac platform that uses a fixed combination of mRNA-encoded, tumor-associated antigens aiming to trigger a strong and precise immune response against cancer. The vaccine candidate is currently being investigated in a Phase 2 trial in patients with anti-PD-1-refractory/relapsed unres...